GSK plc is listed among the 12 Best European Dividend Stocks to Buy Now. JPMorgan lowered GSK’s price target to 1,440 GBp while maintaining an Underweight rating. GSK shares have risen nearly 40% in 2025 due to strong third-quarter results. Specialty Medicines division grew 16% to £3.4 billion.

Oncology sales increased by almost 39%, reflecting the strength of GSK’s new drug portfolio. The company’s performance has been supported by positive clinical updates, especially for respiratory biologics and RSV vaccine. GSK plc is a British multinational pharmaceutical company specializing in medicines, vaccines, and general medicines.

Read more at Yahoo Finance: JPMorgan Lowers GSK Price Target, Maintains Underweight Rating